Objective: The aim of this paper is to describe discontinuation syndromes associated with abrupt and tapered withdrawal of venlafaxine, and to document that withdrawal symptoms may occur after missing a single dose. Clinical picture: We report on two patients prescribed venlafaxine. One developed a broad range of serious side effects after reaching a dose of 300 mg a day, and a severe withdrawal syndrome (including hallucinations) during a slow taper regime. The second had severe discontinuation symptoms during and aborting a slow taper regime, and described withdrawal responses after missing a single dose of venlafaxine.
Conclusions: As for the short-acting selective serotonin re-uptake inhibitors, severe discontinuation reactions may occur with venlafaxine, seemingly marked most distinctly by headache, nausea, fatigue, dizziness and dysphoria, and may make cessation of the drug extremely difficult. Two strategies for addressing the concern are considered.
ClercGERuimyPVerdeau-PaillesJ.A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology1994; 9:139–143.
2.
Victorian Drug Usage Advisory Committee.Psychotropic drug guidelines. 3rd ed.Melbourne: VMF Therapeutics Committee, 1995.
3.
CouplandNJBellCJPotokarJPSerotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology1996; 16:356–362.
4.
SchatzbergAFHaddadPKaplanEMSerotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Journal of Clinical Psychiatry1997; 58:5–10.
5.
BenazziF.Venlafaxine withdrawal symptoms. Canadian Journal of Psychiatry1996; 41:487.
6.
FarahALauerTEPossible venlafaxine withdrawal syndrome. American Journal of Psychiatry1996; 153:576.
7.
LouieAKLannonRAKirschMALewisTBVenlafaxine withdrawal reactions. American Journal of Psychiatry1996; 153:1652.
8.
RauchSLO'SullivanRLJenikeMAOpen treatment of obsessive–compulsive disorder with venlafaxine: a series of ten cases. Journal of Clinical Psychopharmacology1996; 16:81–83.
9.
GiakasWIDavisSMWithdrawal from venlafaxine treated with fluoxetine. Psychiatric Annals1997; 27:85–92.
10.
RosenbaumJFZajeckaJ.Clinical management of antidepressant discontinuation. Journal of Clinical Psychiatry1997; 58:37–40.
11.
AyraDKLithium-induced neurotoxicity at serum lithium levels within the therapeutic range. Australian and New Zealand Journal of Psychiatry1996; 30:871–873.
12.
MulyECMcDonaldWSteffensDBookS.Serotonin syndrome produced by a combination of fluoxetine and lithium. American Journal of Psychiatry1993; 150:1565.
13.
SternbachH.The serotonin syndrome. American Journal of Psychiatry1991; 148:705–713.
